In a rare interview, Panamanian mogul Stanley Motta weighs his country’s potential for growth in infrastructure and capital markets. He does not rule out M&A for Copa.
Category: People
Investment Bank Compensation: Brazil Pay Leads EM
As competition to attract talent intensifies, Brazilian investment bank pay could spiral out of control. Upwards salary pressure shows no signs of abating.
Bill Rhodes: The LatAm Moment
Veteran banker Bill Rhodes says shifts in global growth create opportunity for LatAm. He predicts a slowdown in the US, which he urges to strengthen ties with the region.
Argentina Corporate Debt: Reapertura?
Fresh borrowing by Argentine corporates and sub-sovereigns dovetails with hopes of the sovereign regaining access. A corporate debt boom is unlikely.
IFC’s Nina Shapiro: Passion for EM
The IFC’s popular treasurer is forced by internal rules to step down. But the irrepressible Nina Shapiro has no intention of quitting emerging markets.
Banco do Brasil Flexes Muscle
Latin America’s biggest bank, Banco do Brasil, is riding high with new lines of international and capital markets business. However, elections may be a spanner in the works.
Boutique 1stWEST Appoints Advisor
Colorado-based M&A boutique 1stWest has appointed Gilberto Cisneros as senior advisor for LatAm. Cisneros is co-founder, president and CEO of the Chamber of the Americas, which organizes trade missions and other activities to foster cross-border business activity in the Americas. In his position Cisneros will guide 1stWEST in its continued expansion efforts throughout LatAm. 1stWEST is focused on the underserved lower middle-market of companies with sales of $10m to $100m.
Vale Heard Spinning Off Fertilizer Unit
Vale is planning to spin off and IPO its fertilizer business, according to wire and local news reports citing remarks from CEO Roger Agnelli. The miner spent $4.59bn in January to buy a controlling stake of fertilizer maker Fosfertil. It could sell shares in the new unit, to be called Vale Fertilizantes, as early as the end of the year, Agnelli says. Vale also plans an expansion of the Bayovar phosphate mine in Peru along with partners Mosaic and Mitsui, and may build a plant to process the mineral into fertilizer.
Darby Plans Country-Specific Mezz Funds
US-based Darby Overseas is working on establishing new country-specific mezzanine funds for LatAm, CEO Richard Frank tells LatinFinance. “A Colombian fund is expected to close soon that will provide both PE and mezzanine financing in the infrastructure space,” says Frank. “We are also looking at Brazil and Mexico to set up more country-specific funds,” he adds. On average, Darby raises between $250m-$300m for its mezzanine and PE funds. Darby introduced mezzanine financing to LatAm about a decade ago, Frank says. The shop has 3 mezzanine funds for LatAm and 6 global funds. “Out of the $1.3bn we have for EM mezzanine finance, about half is focused on LatAm,” he says. Frank adds that the funds offer returns in the high teens and low 20s over an average of 6 years. Darby’s original mezzanine fund, DLAMF I, is down to its last 2 investments, 1 in Colombia and the other in Mexico, both of which are in a sale process. The fund closed at $196m in 2008. Frank explains that Darby began offering mezzanine funding because it often found excellent companies whose owners do not want dilution or to give up control. However, they do want risk capital to be able to grow. “With mezzanine financing, they can get risk capital for expansion without giving up a huge ownership stake,” he says. In almost every case, Darby takes a quasi-equity stake of between 5%-15%, investing between $15m-$30m on average, says Frank.
Brazil Pharma Eyes More Deals
Brazil Pharma, the retail pharmaceutical arm of BTG Pactual, is in talks to acquire equity stakes in 2 more Brazilian pharmacy chains, CEO Andre Sa tells LatinFinance. Sa was speaking just a day after the company announced it was acquiring a “co-controlling stake” in Rosario Distrital, whose sales totaled BRL290m in 2009. In the next 18 months Brazil Pharma plans to invest up to $500m, he says, without disclosing how much it paid for Rosario Distrital. “If we do invest in these other 2 chains, they will remain separate from Rosario Distrital,” Sa explains, adding that the deals should be closing by the end of the year. Brazil Pharma’s investment in Rosario Distrital, which is said to give it a 40% stake in the chain, will allow the chain to open 30 stores per year during the next 3 years. It currently has 80. “There are 2 types of drug stores in Brazil: one type serves the high-income population and sells brand-name drugs while the other, which caters to the middle and low-income population, sells generic drugs. We will focus on the latter,” Sa says.
